Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who are suspected of having a new diagnosis of AML (a type of blood cancer) or MDS (a bone marrow disorder), and for whom a specific type of diagnostic genetic test through Barnes-Jewish Hospital has been requested or is planned to be requested.
- People who are able to understand and are willing to sign a written consent form approved by the ethics review board.
- Treating doctors at Washington University School of Medicine who manage care for patients with blood cancers may also participate as physician participants in this trial.
- Physician participants must be willing and able to complete standardised questionnaires about their experience using a testing process called ChromoSeq.
Who may not be able to join:
- People under 18 years of age are not eligible as patient participants.
- Doctors who do not treat patients at Washington University School of Medicine are not eligible as physician participants.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Meagan Jacoby, M.D., Ph.D., Washington University School of Medicine
Phone: 314-747-8439
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of ChromoSeq as measured by total number of recurrent structural variants identified; Sensitivity of ChromoSeq as measured by total number of copy number alterations identified; Sensitivity of ChromoSeq as measured by number of single nucleotide variants identified; Sensitivity of ChromoSeq as measured by number of insertion-deletions identified; Determine if risk-stratification using ChromoSeq correlates with overall-survival; Determine if risk-stratification using ChromoSeq correlates with event-free survival; Proportion of cases in which ChromoSeq provides new genetic informatio...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.